share_log

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K：重大事件
美股SEC公告 ·  10/28 17:20

Moomoo AI 已提取核心信息

On October 22, 2024, Panbela Therapeutics, Inc. entered into a significant financial agreement with Nant Capital, LLC. Under the terms of the Note Purchase Agreement, Panbela Therapeutics issued a Senior Convertible Promissory Tranche A Note for $2,850,000 and committed to issuing a Tranche B Note for $9,150,000 by November 15, 2024. These notes, bearing interest at a rate of 8.00% plus the Monthly SOFR Rate, are convertible into common stock at $0.37 per share and are due six months from the issuance date or earlier under certain conditions. The proceeds from the notes will be allocated to general corporate purposes and repayment of existing debts. The agreement also includes a guaranty by Panbela's subsidiaries, Cancer Prevention Pharmaceuticals, Inc. and Panbela Research, Inc., ensuring the fulfillment of the company's obligations under the agreement. The sale of the notes is part of a private placement exempt from registration under the Securities Act of 1933.
On October 22, 2024, Panbela Therapeutics, Inc. entered into a significant financial agreement with Nant Capital, LLC. Under the terms of the Note Purchase Agreement, Panbela Therapeutics issued a Senior Convertible Promissory Tranche A Note for $2,850,000 and committed to issuing a Tranche B Note for $9,150,000 by November 15, 2024. These notes, bearing interest at a rate of 8.00% plus the Monthly SOFR Rate, are convertible into common stock at $0.37 per share and are due six months from the issuance date or earlier under certain conditions. The proceeds from the notes will be allocated to general corporate purposes and repayment of existing debts. The agreement also includes a guaranty by Panbela's subsidiaries, Cancer Prevention Pharmaceuticals, Inc. and Panbela Research, Inc., ensuring the fulfillment of the company's obligations under the agreement. The sale of the notes is part of a private placement exempt from registration under the Securities Act of 1933.
2024年10月22日，Panbela Therapeutics公司与Nant Capital, LLC达成了一项重要的财务协议。根据《票据购买协议》的条款，Panbela Therapeutics发行了价值285万美元的高级可转换Tranche A票据，并承诺在2024年11月15日前发行价值915万美元的Tranche b票据。这些票据的利率为8.00%，加上月度SOFR利率，可按0.37美元/股转换为普通股，到期日为发行日后六个月，或在某些条件下提前到期。票据的收益将用于一般公司用途和偿还现有债务。协议还包括Panbela子公司Cancer Prevention Pharmaceuticals, Inc.和Panbela Research, Inc.的担保，确保公司履行协议下的义务。该票据的出售属于根据1933年证券法豁免登记的私募。
2024年10月22日，Panbela Therapeutics公司与Nant Capital, LLC达成了一项重要的财务协议。根据《票据购买协议》的条款，Panbela Therapeutics发行了价值285万美元的高级可转换Tranche A票据，并承诺在2024年11月15日前发行价值915万美元的Tranche b票据。这些票据的利率为8.00%，加上月度SOFR利率，可按0.37美元/股转换为普通股，到期日为发行日后六个月，或在某些条件下提前到期。票据的收益将用于一般公司用途和偿还现有债务。协议还包括Panbela子公司Cancer Prevention Pharmaceuticals, Inc.和Panbela Research, Inc.的担保，确保公司履行协议下的义务。该票据的出售属于根据1933年证券法豁免登记的私募。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间